Reference Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Ref Type
Authors GL. Uy, J Godwin, MP Rettig, N Vey, M Foster, ML. Arellano, DA. Rizzieri, MS. Topp, G Huls, B Lowenberg, G Martinelli, S Paolini, F Ciceri, MG Carrabba, C Ballesteros-Merino, CB Bifulco, H Lelièvre, R La Motte-Mohs, D Li, J Sun, K Jacobs, K Spohn et. al.
Title Preliminary Results of a Phase 1 Study of Flotetuzumab, a CD123 x CD3 Bispecific Dart Protein, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
Journal Blood
Abstract Text Blood 2017 130(Suppl 1):637


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Flotetuzumab Flotetuzumab 1 2
Drug Name Trade Name Synonyms Drug Classes Drug Description
Flotetuzumab MGD006|S80880 Flotetuzumab (MGD006) is a humanized bispecific antibody that targets both CD123 and CD23, which may lead to anti-leukemic activity (Blood 2017 130(Suppl 1):637, PMID: 32493790).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown acute myeloid leukemia not applicable Flotetuzumab Phase I Actionable In a Phase I trial, Flotetuzumab (MGD006) demonstrated safety and preliminary efficacy in patients with relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome, resulted in anti-leukemic activity in 57% (8/14) of patients and an overall response rate of 43% (6/14, 3 complete response, 1 CRi, 1 MLF, 1 partial response) (Blood 2017 130(Suppl 1):637). detail...